Immune-focused RBD nanoparticles induce cross-reactive, RBS-directed responses capable of variant-resistant SARS-CoV-2 neutralization. - Konrath KM; Liaw K; Tursi NJ; McCanna ME; Warner BM; Gary EN; Zhu X; Livingston C; Monastra C; Frase D; Chokkalingam N; Huynh A; et al. (PLoS pathogens, 2026)